<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-DJD5ICLH</identifier><date>2013</date><creator>Petre, Maja</creator><relation>documents/doc/D/URN_NBN_SI_doc-DJD5ICLH_001.htm</relation><relation>documents/doc/D/URN_NBN_SI_doc-DJD5ICLH_001.pdf</relation><relation>documents/doc/D/URN_NBN_SI_doc-DJD5ICLH_001.txt</relation><format format_type="issue">1</format><format format_type="volume">64</format><format format_type="type">article</format><format format_type="extent">str. 25-32</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID">26965543</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-DJD5ICLH</identifier><language>slv</language><publisher>Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="slv">antikoagulanti</subject><subject language_type_id="slv">apiksaban</subject><subject language_type_id="slv">dabigatran</subject><subject language_type_id="eng">drug</subject><subject language_type_id="slv">rivaroksaban</subject><subject language_type_id="slv">zdravila</subject><title>Latest clinical trials and approved indications of new oral anticoagulants</title><title>Predstavitev novih raziskav in odobrenih indikacij pri novih peroralnih antikoagulantih</title></Record>